Update on Type 1 Diabetes Activities

Judith Fradkin, M.D.

Director, Division of Diabetes,
Endocrinology, and Metabolic
Diseases, NIDDK

Purpose

• Apprise you of the implementation status of recommendations from the January planning and evaluation meeting of the Special Statutory Funding Program for Type 1 Diabetes Research

Solicit your input and participation


Recommendation: Initiate a much broader review of the entire state-of-the-science with respect to type 1 diabetes.

T1D Strategic Planning Effort: Recent Advances and Emerging Opportunities

The Strategic Plan will be Framed Around Six T1D Research Goals

- Identify Genetic & Environmental Causes
- Prevent or Reverse T1D
- Develop Cell Replacement Therapy
- Prevent or Reduce Hypoglycemia
- Prevent or Reduce Complications
- Attract New Talent & Apply New Technologies

Conceptual Framework for Development of T1D Strategic Plan (a work product of the DMICC)



Charge to Working Groups

 Identify major research advances in T1D research that have occurred since 1998;

 Identify emerging opportunities in T1D research that can be pursued by the NIH or other HHS agencies in the next 10 years.

Planned Timeline

DATE	TASK
April 15	Identify and extend invitation to outside experts
Mid-May	First conference calls of WG members to discuss advances and opportunities
Summer 2005	WG chairs write chapters in consultation with WG members
Sept 2005	Meeting of the Executive Committee to integrate chapters
Fall 2005	DMICC review of DRAFT report
Winter 2005	Public comment period
Spring 2006	Review of final document—DMICC members and NIH ICs
June 2006	Final Document

Request for Participation

- NIH IC and Agency Representatives to serve as liaisons on the 5 Working Groups and/or Executive Committee;
- Suggestions for external scientists and lay representatives to serve on Working Groups;
- By March 31 please provide names of representatives and external scientists to: Dr. Mary Hanlon, hanlonm@extra.niddk.nih.gov

Recommendation: Support "self-assembled" teams of scientists who tackle a specific barrier in type 1 diabetes research.

Self-Assembled Consortia: Possible Grand Challenges

- Development of assays and biomarkers useful for assessing response to immunomodulatory interventions in T1D;
- Development of methods to image beta cell mass and immune infiltration of the pancreas;
- Development of biomarkers for complications;
- Development of outcome measures that could enable complications trials to be done with shorter durations/fewer patients

Self-Assembled Consortia: Implementation Plans

- Up to 3 awards for each challenge will be supported for 3 years (FY 06-08) at up to \$400K DC;
- Awards will use P20 mechanism to facilitate milestone-driven team-building and pilot and feasibility projects;
- It is planned that highly successful projects will compete for 5 years of funding beginning in FY09 if funds are available.

Recommendation: Existing consortia and resources should have External Advisory Committees.

Recommendation: Enhance coordination among existing consortia and resources.

Enhance Coordination: Implementation Plans

- Joint meeting of representatives of each major consortia and resource to consider opportunities for collaboration, common bioinformatics, etc.;
- Joint meeting of TrialNet, ITN, and CIT investigators;
- Joint meeting of T1DGC, GoKinD, FIND and EDIC genetics investigators;
- Joint meeting of TEDDY, TRIGR and NIP investigators.